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Exona b s t r a c t
Background: Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopa-
thy (CADASIL) is a monogenic, hereditary, neurological syndrome characterized by small vessel disease
(SVD), stroke, vascular cognitive impairment and dementia. It is caused by mutations in the NOTCH3
gene, affecting the number of cysteines in the extracellular domain of the receptor, causing protein mis-
folding and receptor aggregation. The pathogenic role of cysteine-sparing NOTCH3 missense mutations in
patients with typical clinical CADASIL syndrome is unknown. No therapies are available for this condi-
tion.
Objective: Genetic study of the NOTCH3 gene in CADASIL patients who were referred to the Fazeli-Sanati
Genetics Laboratory.
Subjects and methods: Peripheral blood samples were collected from 10 CADASIL patients to extract geno-
mic DNA. DNA sequences of exons 2–8, 11–12 and 18–19, where NOTCH3mutations are typically located;
were amplified by using PCR and analyzed by direct sequencing.
Results: 11 NOTCH3 exons were analyzed. Homozygous IVS7 + 15A>G mutation were found in five
patients, Homozygous IVS7 + 16A>G mutation in one patient, Heterozygous for the Pro109Thr and
Pro203His mutations in one patient, which were not reported previously. Heterozygous C395R and
R153C mutations were found in two patients. One of the patients has no mutation in 11 analyzed
NOTCH3 exons.
Conclusion: We found four novel mutations (P109T, P203H, IVS7 + 15A>G and IVS7 + 16A>G) and 2
reported NOTCH3 mutations. Exon 4 and Intron 7 are hotspots in the patients we examined with the
NOTCH3 mutations. These findings broaden the mutational spectrum of CADASIL.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) is an adult-onset
inherited small artery disease characterized by non-hypertensive,
non-arteriosclerotic, small arterial granular degeneration [1,2].The main clinical manifestations of CADASIL are progressive
white matter lesions and recurrent strokes leading to disability,
migraine with aura and dementia with early death [3–6].
In the case of CADASIL the presence of granular osmiophilic
material (GOM), in close association with smooth muscle cells, per-
icytes and endothelial cells are very important for diagnosis [7,8].
The other critical point is analyzing all the exons of the NOTCH3
gene to find the mutation that causes the pathology [6,9].
The mean age of onset of clinical symptoms is the mid-forties
(for stroke onset is approximately 46 years; for dementia, the
mean age of onset is 55) [10]. However, in recent studies, 52 years
for males and 57 for females have been described [11]. CADASIL
has been reported in various populations worldwide [5,12].
Table 1
The NOTCH3 gene mutations reported in the present study.
Patient number Gender Age NOTCH3 mutation Exon Intron Homozygous/Heterozygous Reported/Novel
1 Male 71 IVS7 + 15A>G 7 Homozygous Novel
2 Female 32 Cys 395 Arg T>C 7 Heterozygous Reported
3 Male 48 Arg 153 Cys C>T 4 Heterozygous Reported
4 Male 42 IVS7 + 16A>G 7 Homozygous Novel
5 Female 51 IVS7 + 15A>G 7 Homozygous Novel
6 Male 70 IVS7 + 15A>G 7 Homozygous Novel
7 Female 22 IVS7 + 15A>G 7 Homozygous Novel
8 Female 44 IVS7 + 15A>G 7 Homozygous Novel
9 Female 26 No mutation in 11 analyzed NOTCH3 exons – – – –
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degeneration and loss of vascular smooth muscle cells [13–15].
NOTCH3 gene is located on the 19p13 chromosome, which encodes
a transmembrane receptor [6,16]. This single-pass transmembrane
receptor consists of three domains: a large extracellular domain
(ECD) with 34 tandem epidermal growth factor-like (EGF) repeats
encoded by exons 2–24, where NOTCH3 mutations are typically
located; a transmembrane domain; and an intracellular domain
(ICD) [7,17,18].
NOTCH3 is composed of 33 exons and 2321 amino acids [13].
The presence of only one mutation in one of the two alleles leads
to CADASIL, because the pathogenic mutations are dominant for
this disease [19].
The studies done so far indicate that almost all of the patho-
genic mutations are missense mutations that result in changes in
the number of cysteines, with a strong clustering of mutations in
exons 4 [14,19], although some studies indicate that there are
mutations associated with CADASIL that do not affect the number
of cysteines. However, the pathogenic role of these mutations is
uncertain [7]. So far more than 230 mutations have been reported
in the NOTCH3 gene, which is associated with CADASIL [6].
In the present study, we examined the NOTCH3 gene mutations
in ten diagnosed CADASIL patients and report four novel splicing
mutations of the NOTCH3 gene.
2. Subjects and methods
A total of 10 CADASIL patients, who were referred to the Fazeli-
Sanati Genetics Laboratory for the detection of the NOTCH3 gene
mutations in genomic DNA were chosen. The subjects participated
in this study with their written informed consent.
Whole blood was collected by venipuncture in tubes containing
EDTA. Genomic DNA was extracted from peripheral blood using
routine procedures. The concentration and purity of DNA samples
were determined by spectrophotometric analysis.
Sequencing of the exons 2–8 and 11, 12, 18, 19 (both coding
regions and intron/exon boundaries), which are mutational hot-
spots of the NOTCH3 gene, was undertaken using PCR amplification
and direct Sanger sequencing. The amplified PCR products of the
NOTCH3 gene visualized on a 2% agarose gel. https://blast.ncbi.
nlm.nih.gov/ was used to align sequences data with NOTCH3 refer-
ence DNA sequence to identify pathogenic mutations.
3. Results
Ten patients diagnosed with CADASIL were selected for this
study. The mean age at the time of collection of CADASIL patients
was 46.3 years. Six out of the ten patients were females (60%) and
four were males (40%). All of the patients were of Iranian origin.
In the total of ten patients, DNA molecular analysis was per-
formed for 11 exons of the NOTCH3 gene. Direct sequencing ofexons 2–8, 11, 12 and 18, 19 and intron/exon boundaries in clini-
cally suspected patients identified 6 mutations.
The mutations were: IVS7 + 15A>G, IVS7 + 16A>G, C395R,
R153C, P109T and P203H (Table 1). Heterozygous missense muta-
tions were identified in exons 7 and 4 (p.Cys395Arg, p.Arg153Cys);
Patient number nine did not involve the mutation in examined
exons of the NOTCH3 gene.
The highest numbers of mutations were found in intron 7 (n =
6), followed by exon 4 (n = 2), Exons 3 and 7, each had one muta-
tion in two patients, and the examined mutations of the NOTCH3
gene are shown in Table 1. The most common mutation was
IVS7 + 15A>G in intron 7.
In total six variants including two known mutations and four
novel mutations in ten patients were identified.4. Discussion
CADASIL is an inherited arteriopathy and a rare neurological
disorder in the general population, but the most frequent non-
atherosclerotic monogenic hereditary degenerative vascular cere-
bral disease [13,20,21]. In 1997 the NOTCH3 gene was found to
be the cause of CADASIL that is composed of 33 exons and its pro-
duct is a 2321 amino acid [13,22,23].
Ten patients with CADASIL from Iranian population were
recruited in the present study and performed genetic sequencing
of the 11 exons of the NOTCH3 gene.
In our study we identified four novel mutations, two homozy-
gous mutations IVS7 + 15A>G in intron 7 of the NOTCH3 gene and
two heterozygous mutations predicting amino acid change from
proline to threonine at position 109 (Pro109Thr) and proline to his-
tidine at nucleotide 203 (Pro203His). Furthermore we identified 2
heterozygous missense mutations (p.Cys395Arg, p.Arg153Cys)
respectively in exons 7 and 4, which do not affect the number of
cysteines, unlike almost all of the pathogenic mutations associated
with CADASIL syndrome. However one of the patients had no
mutation in the considered exons of the NOTCH3 gene.
Our findings broaden the mutation spectrum of NOTCH3 and
suggest that in patients with CADASIL should consider the
sequencing of the 11 exons in NOTCH3 gene.
In German, Greek, Caucasian and Japanese populations the
NOTCH3 mutations were previously showed to cluster in exons
2–6, especially in exon 4 [24–30]. In Chinese populations higher
frequency of mutations were clustered in exons 3, 4, 11 [20,31].
The NOTCH3 gene analysis revealed mutations on exons 22 in
Kashmir and Italian patients [2,32,33].
In Italian studies the highest percentage of mutations were
found in exons 3 and 4, but in exons 4 and 11 was noted in the cen-
ter and characterized by a recurrent mutation p.Arg607Cys [20,34].
In another study a heterozygous deletion mutation was identified
in intron 3 (c.341-26_24delAAC) [35].
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contributed the most and p.Arg544Cys were relatively common,
while the ratio of mutations in exon 4 was extremely low [20,36].
In our study which included patients from Iran, the intron 7 and
exon 4 were considered to be a ‘‘hot region‘‘. Nevertheless the
mutation IVS7 + 15A>G was ranked in the first place of the muta-
tional spectrum in our subjects.
Analyses of four novel mutations were identified in this study in
other family members of the patients to confirm these findings and
complete investigation of the NOTCH3 gene, using NGS method,
would be needed in future studies.
In addition, for one of the patients who had no mutations in her
examined exons, despite the presence of symptoms of CADASIL,
analysis of other exons of the NOTCH3 gene is suggested.
5. Conclusion
We found four novel mutations and 2 reported NOTCH3 muta-
tions in CADASIL patients that expand the genetic spectrum of this
disease. Our work also indicates that NOTCH3 mutations are clus-
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